AEProbio
Alliance for Education on Probiotics

2023



Guide Clinique des

Produits Probiotiques

vendus au Canada : 15e Édition

Renseignements posologiques | Applications | Données cliniques publiés à ce jour

Table des matières

Auteure
Dragana Skokovic-Sunjic
BScPhm RPh NCMP

Réviseurs médicaux
Dr Vivien Brown
MDCM CCFP FCFP NCMP
Iris Krawchenko
BScPhm RPh ACPR
Dr Ruben Hummelen
MD MSc PhD CCFP
Dr John Marshall
MD MSc FRCPC AGAF
Dr Tom Smiley
BScPhm PharmD

Éditrice
Rebecca L. Johnson
PhD candidate

ISBN: 978-1-7775181-4-1

Acronymes :

APLV	Allergie aux protéines du lait de vache *(y compris coliques attribuables à l'APLV)*
C	Constipation
CV	Candidose vulvo-vaginale
Coliques	Coliques
DAA	Diarrhée associée aux antibiotiques - *Prévention*
DACD	Diarrhée associée à Clostridium difficile - *Prévention*
DAF	Douleur abdominale fonctionnelle
DI	Diarrhée infectieuse
DV	Diarrhée du voyageur - *Prévention*
EI/DA	Eczéma infantile / Dermatite atopique
GP	Gestion du poids *(aide à réduire le poids corporel, la masse grasse, et le tour de taille)*
H/A	Humeur et affect *(symptômes liés au stress / à l'anxiété, pas un substitut au traitement standard)*
HP	Helicobacter pylori – *Comme complément au traitement d'éradication standard*
IN	Prévention des infections nosocomiales - *infections contractées à l'hôpital*
LDL-C	Réduction des LDL et du cholestérol total
MIC	Maladies infectieuses courantes - *acquises dans la collectivité*
MICI-CU	MICI - Colite ulcéreuse – *comme complément à la thérapie standard*
MICI-P	Maladies inflammatoires chroniques de l'intestin *(pochite)*
Mastite	Mastite chez les mères allaitantes *(traitement et prévention)*
NEC	Entérocolite nécrosante *(nouveau-né) *conformément au protocole hospitalier, et non à des fins d'autoadministration*
Regurg/ Mot intestinal	Réduit la régurgitation/améliore la motilité intestinale gastrointestinale
SBD	Santé bucco-dentaire *(réduction de l'amygdalite, de la laryngite et de la carie dentaire)*
SCI	Syndrome du côlon irritable
SF	Santé du foie *(NASH/NAFLD/MHE;comme adjuvant à la thérapie standard; voir des études pour une population spécifique)*
VB	Vaginose bactérienne

Guide Clinique des Produits Probiotiques vendus au Canada

Ce Guide se veut un outil pratique d'aide à la prise de décisions cliniques axées sur la thérapie probiotique destinée à vos patients.

Ce Guide clinique est conçu de manière à utiliser les données scientifiques sur les produits probiotiques pour en extraire des renseignements cliniques pratiques et pertinents. Il est destiné à être utilisé comme outil d'aide à la prise de décisions cliniques par les cliniciens, et vise à leur permettre de sélectionner facilement le produit, la dose et la préparation appropriés pour une indication précise.

Notre objectif est de favoriser le choix du bon produit et de la bonne souche de probiotiques, en vue d'obtenir les résultats souhaités. Le présent Guide clinique ne se veut ni une revue systématique ni une « ligne directrice de pratique clinique. » Il ne doit aucunement permettre aux entreprises de faire des allégations en matière de santé dans le cadre de la commercialisation de leurs produits.

À l'heure actuelle, la somme des données sur les probiotiques augmente constamment, de même que la demande générale pour ces produits. Des données permettent d'appuyer l'utilisation de probiotiques pour diverses indications, qui dépassent la santé intestinale. Il faut cependant noter que l'usage clinique et les résultats sont spécifiques à chaque souche.

En raison des changements fréquents en matière de disponibilité commerciale des souches de probiotiques, des nouvelles données publiées, et de la recherche croissante, une révision et des mises à jour du Guide Clinique ont été effectuées annuellement depuis 2008. L'absence générale d'effets indésirables attribuables aux probiotiques vient appuyer l'utilisation répandue de ces produits, mais les recherches doivent tout de même se poursuivre.

Comment le Guide est-il mis à jour ?

Une revue systématique des articles portant sur des critères d'inclusion prédéterminés a été entreprise afin de faire ressortir les études ayant des résultats cliniques précis concernant des souches précises de probiotiques. Des produits disponibles sur le marché contenant ces souches ont été identifiés, et les niveaux de preuves ont été utilisés pour évaluer l'ampleur des bienfaits escomptés. Ces renseignements ont été compilés, puis présentés sous forme de tableaux.

Les données ont été évaluées par un groupe de réviseurs experts indépendants. Dans le cas des probiotiques, les données cliniques doivent être liées à des préparations précises (telles que définies par : le genre, l'espèce, la souche, la désignation alphanumérique et le nombre de bactéries actives, ainsi que le mélange de souches de probiotiques et les ingrédients inactifs).

L'auteure et les réviseurs ont travaillé d'arrache-pied afin d'inclure les données cliniques publiées concernant les préparations de probiotiques offertes sur le marché. Afin d'éviter un penchant pour la sélection en ce qui a trait à des préparations précises, les recherches ont été menées dans deux bases de données distinctes (soit PubMed et EMBASE), et des experts indépendants ont été embauchés pour faire ressortir les études publiées et non publiées.

Pourquoi inclure uniquement un nombre limité de produits ?

Tous les critères d'inclusion énumérés ci-dessous doivent être satisfaits pour qu'un produit figure dans le Guide Clinique :

1. Le produit doit être commercialisé au Canada (ou aux États-Unis) à titre de supplément ou d'aliment contenant des probiotiques.
2. Le produit doit contenir des souches de probiotiques qui sont reconnues comme ayant un statut « sans danger » (FDA) et/ou il doit posséder un numéro de produit santé naturel (Santé Canada).
3. Chaque produit doit s'accompagner d'études cliniques favorables publiées concernant les souches particulières qu'il contient.
4. Lorsqu'un produit contient plusieurs souches de probiotiques, les données doivent se rapporter à la préparation du produit, et ne doivent pas être extrapolées à partir d'études concernant certaines des souches distinctes de probiotiques qui sont contenues dans le produit.

Note : *Certains produits sont exclus de la présente édition en raison des changements dans les souches utilisées.*

Renseignements cliniques : *Les indications en matière d'utilisation sont basées sur les souches spécifiques ou sur les combinaisons de souches ayant fait l'objet d'études.*

Attention : *L'extrapolation des données et des recommandations du présent Guide à d'autres combinaisons de souches probiotiques n'est pas autorisée.*

Niveau de recommandation :

Level I	Niveau I : Données provenant d'au moins un essai conçu de manière appropriée (randomisation, mise en insu, comparaisons de la population appropriée) avec un calcul puissance pour le(s) résultat(s) d'intérêt(s). Le conseil de réviseurs experts se réservent le droit de prendre la décision finale concernant le niveau de la recommandation. **(NIVEAU LE PLUS ÉLEVÉ)**
Level II	Données provenant des essais bien conçus et contrôles sans de la randomisation ; données provenant des essais randomisés ne satisfaisant pas à tous les critères de niveau I. Données provenant d'études de plusieurs séries chronologiques, avec ou sans intervention. On peut également considérer que les résultats spectaculaires provenant d'études non comparatives appartiennent à ce niveau de preuve.
Level III	Opinions d'autorités en la matière qui se basent sur leur expérience clinique, sur des études descriptives ou des rapports de comités d'experts.

Les lecteurs sont fortement encouragés à examiner les preuves répertoriées pour chaque produit. Veuillez consulter les publications individuelles pour de plus amples renseignements concernant les populations de patients étudiées (par ex. par âge, sexe et comorbidités) ainsi que les détails concernant l'effet clinique (signification statistique, ampleur de l'effet du traitement et précision des intervalles de confiance).

Limitation de responsabilité

Veuillez faire parvenir vos questions ou commentaires à **DSunjic@bhsoftinc.com**

Version 2023, dernière modification janvier 2023, valide jusqu'au 31 décembre 2023. ©BHSoftInc

Produits probiotiques pour **la santé digestive et hépatique de la population adulte :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	C	HP	DACD	SCI	DI	DAA	MICI-P	DV
Align®	*B. longum* 35624	Capsule	1mds/capsule	1 capsule				I (1-4)				
Align® Chewables		Comp. à mâcher	1mds/comp. à mâcher	1 comp. à mâcher								
Bio-K+ Antibio Pro Produit stable à temperature pièce et option réfrigérée disponible	*L. acidophilus* CL1285 *L. casei* LBC80R *L. rhamnosus* CLR2	Capsule	50mds/capsule	1-2 capsules								
Bio-K+ BiomePRO 100M Probiotique liquide		Liq. de riz fermenté	100mds/pot	0.5-1 pot par jour			I (6-10)			I (5-7)		
Bio-K+ Probiotiques à boire		Liq. de lait fermenté Liq. végétalien fermenté	50mds/pot 50mds/pot	1 pot 1 pot								
Bio-K+ SCI Pro Produit stable à temperature pièce et option réfrigérée disponible		Capsule	50mds/capsule	2 capsules				I (18)				
BioGaia® Protectis® Bébé Gouttes	*L. reuteri* DSM 17938	Gouttes	100mns/5 gouttes	5 gouttes	I (17)	I (13-16)			II (11)	II (12)		
BioGaia® Protectis® Comprimés Croquables		Comp. à mâcher	100mns/comp. à mâcher	1 comp. à mâcher								
BioGaia® Protectis® Gouttes avec Vitamine D		Gouttes	100mns/5 gouttes	5 gouttes								
BioGaia® Junior Protectis® Comprimés avec Vitamine D		Comp. à mâcher	100mns/comp. à mâcher	1 comp. à mâcher								
Biomed Bacillus Coagulans	*Bacillus coagulans* MTCC 5856	Capsule	1mds/capsule	2 capsules				II (19)				
Culturelle® Digestive Daily Probiotic Chewables	*L. rhamnosus* GG	Comp. à mâcher	10mds/comp. à mâcher	1 comp. à mâcher		I (24)	III (25-27)			I (23)	II (28)	II (29-30)
Culturelle® Digestive Health Daily Probiotic Capsules		Capsule	10mds/capsule	1 capsule								

❄ - Le produit nécessite une réfrigération
- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Produits probiotiques pour **la santé digestive et hépatique de la population adulte :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	MICI-CU	HP	DACD	SCI	DAA	DV
Digestive Care™ 10 Billion Daily Probiotic	*L. plantarum* 299v	Capsule	10mds/capsule	1-2 capsules			III (32,36)	I (33-35)	III (31)	
FlorastorMax®	*Saccharomyces boulardii lyo* CNCM I-745	Sachet	10mds/sachet	1 sachet	III (43,47-50)	I (44-46)	I (8-9,38-39,51)		I (37-38)	I (40-42)
Florastor®		Capsule Sachet	5mds/capsule 5mds/sachet	1-2 capsules 1-2 sachets						
HMF **Forte**	*L. acidophilus* CUL-60 *L. acidophilus* CUL-21 *B. animalis subsp. lactis* CUL-34 *B. bifidum* CUL-20	Capsule	10mds/capsule	2-3 capsules						
HMF **IBS Relief**		Capsule	25mds/capsule	1 capsule						
HMF **Intensive**		Capsule	25mds/capsule	1 capsule			II (52)	II (53)		
HMF **Intensive 50**		Capsule	50mds/capsule	1 capsule						
HMF **Intensive Powder**		Poudre	25mds/1 mesure *(1 gramme)*	1 mesure						
HMF **Super Powder**		Poudre	10mds/1 mesure *(1 gramme)*	2-3 mesures						
Mutaflor®	*Echerichia coli Nissle* 1917	Capsule	2.5-25mds/capsule	1-2 capsules	I (57-60)					
Pregnancy Care Probiotic	*L. rhamnosus* R0011 *L. helveticus* R0052	Capsule	2mds/capsule	1-2 capsules				III (69)		
Probiotic 10 Billion Active Cells Daily Maintenance	*Lactococcus lactis* (UALI-08) *L. gasseri* (UALg-05) *L. rhamnosus* (UALr-06) *B. animalis subsp. lactis* (UABla-12) *B. breve* (UABbr-11) *L. paracasei* (UALpc-04) *L. rhamnosus* (UALr-18) *L. acidophilus* (DDS©-1) *L. plantarum* (UALp-05) *B. longum* subsp. longum (UABl-14) *B. bifidum* (UABb-10) *L. casei* (UALc-03) *L. reuteri* (UALre-16) *B. longum* subsp. infantis (UABi-13)	Capsule	10mds/capsule	3 capsules	II (68)					

- Le produit nécessite une réfrigération
- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

www.ProbioticChart.ca

Produits probiotiques pour **la santé digestive et hépatique de la population adulte :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	C	MICI-CU	DACD	SCI	DAA	MICI-P	SF
Purica Probiotic Intensive GI	*L. plantarum* CECT7484/ KABP022® *L. plantarum* CECT7485/ KABP023® *P. acidilactici* CECT7483/ KABP021®	Capsule	3mds/capsule	1 capsule				I (73-74)			
Ultra Probiotic Complex by GNC	*L. acidophilus* CUL-60 *L. acidophilus* CUL-21 *B. bifidum* CUL-20 *B. lactis* CUL-34	Paquet Capsule	25mds/paquet 25mds/ 50mds/ 75mds par capsule	1-2 paquets 1-2 capsules			II (52)	II (53)			
UltraFlora® Balance	*L. acidophilus* NCFM® *B. lactis* Bi-07®	Capsule	15mds/capsule	2 capsules				II (78)			
UltraFlora® Intensive Care	*L. plantarum* 299v	Capsule	10mds/capsule	2 capsules			III (32,36)	I (33-35)	III (31)		
UltraFlora® Restore	*B. lactis* Bi-07® *L. acidophilus* NCFM® *B. lactis* BI-04 *L. paracasei* Lpc-37	Capsule	20mds/capsule	1 capsule					I (75-76)		
Visbiome® *Cette combinaison de souches est connue sous le nom de la formulation du prof. De Simone et est la même que celle mentionnée dans les références qui citent VSL #3 comme schéma thérapeutique*	*L. acidophilus* DSM24735/ SD5212 *L. paracasei* DSM24733/ SD5218 *L. delbrueckii subsp. bulgaricus* DSM24734/SD5210 *L. plantarum* DSM24730/ SD5209 *B. longum* DSM24736/SD5220 *B. infantis* DSM24737/SD5219 *B. breve* DSM24732/SD5206 *S. thermophilus* DSM24731/ SD5207	Sachet	450mds/ sachet	1-4 sachets	II (81,92)	I (82-84)				I (83,85-87)	I (88-91,93-94)

- Le produit nécessite une réfrigération
- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Produits probiotiques pour **la santé générale de la population adulte :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	MIC	SBD	GP	LDL-C	H/A
BioGaia® ProDentis™	*L. reuteri* ATCC PTA 5289 *L. reuteri* DSM 17938	Pastille	200mns/pastille	1 pastille		I (63-67)			
Calm Biotic®	*B. longum* R0175 *L. helveticus* R0052	Capsule	3mds/capsule	1 capsule					II (20-22)
CulturedCare® Probiotic Gum with BLIS K12®	*Streptococcus salivarius* K12	Pastille	0.5mds/pastille	2-10 pastilles		II (61-62)			
HMF Metabolic	*L. acidophilus* CUL-60 *L. acidophilus* CUL-21 *B. animalis subsp. lactis* CUL-34 *B. bifidum* CUL-20 *L. plantarum* CUL-66	Capsule	50mds/capsule	1 capsule			II (54)		
Purica Probiotic Cardio	*L. plantarum* CECT7257/ KABP011® *L. plantarum* CECT7258/ KABP012® *P. acidilactici* CECT7259/ KABP013®	Capsule	1mds/capsule	1 capsule				II (70-72)	
Probiotic Sticks	*B. longum* R0175 *L. helveticus* R0052	Sachet de la poudre	3mds/sachet	1 sachet					II (20-22)
UltraFlora® Control	*B. animalis ssp. lactis* 420 (B420™)	Capsule	10mds/capsule	1 capsule			I (77)		
UltraFlora® Cold Support	*L. plantarum* HEAL9 *L. paracasei* 8700:2	Capsule	1mds/capsule	1 capsule	I (79-80)				

- Le produit nécessite une réfrigération
- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Produits probiotiques pour **la population pédiatrique :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	DAA	C	EI/DA	MIC	Coliques	DAF	SCI	DI	NEC	SBD	Regurg/Mot intestinal
BioGaia® Protectis® Bébé Gouttes	*L. reuteri* DSM 17938	Gouttes	100mns/5 gouttes	5 gouttes	I (107)	I (108-109)	II (114-115)	I (112-113)	I (98-101,116-117)	I (110-111)	I (110-111)	I (102-106)	I (118-120)		I (95-97)
BioGaia® Protectis® Comprimés Croquables	*L. reuteri* DSM 17938	Comp. à mâcher	100mns/comp. à mâcher	1 comp. à mâcher	I (107)	I (108-109)	II (114-115)	I (112-113)	I (98-101,116-117)	I (110-111)	I (110-111)	I (102-106)			I (95-97)
BioGaia® Protectis® Gouttes avec Vitamine D	*L. reuteri* DSM 17938	Gouttes	100mns/5 gouttes	5 gouttes	I (107)	I (108-109)	II (114-115)	I (112-113)	I (98-101)	I (110-111)	I (110-111)	I (102-106)			I (95-97)
BioGaia® Junior Protectis® Comprimés avec Vitamine D		Comp. à mâcher	100mns/comp. à mâcher	1 comp. à mâcher											
BioGaia® ProDentis™	*L. reuteri* ATCC PTA 5289 *L. reuteri* DSM 17938	Pastille	200mns/pastille	1 pastille										I (63-67,157-159)	
CulturedCare® Probiotic Gum with BLIS K12®	*Streptococcus salivarius* K12	Pastille	1mds/pastille	1-5 pastilles										II (61-62)	

- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Produits probiotiques pour **la population pédiatrique :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	DAA	DACD	EI/DA	MIC	Coliques	DAF	HP	SCI	DI	SF	IN
Culturelle® Kids Daily Probiotic Chewables	*L. rhamnosus* GG	Comp. à mâcher	5mds/comp. à mâcher	2-4 comp.s à mâcher	I (127-128)		I (132-138,143)	I (142)		I (129-130)		I (129-130)	I (121-126,141)	II (139-140)	I (131)
Culturelle® Kids Daily Probiotic Packets		Poudre	5mds/paquet	2-4 paquets											
Ddrops Bébé	*B. longum* CECT7894/ KABP042® *P. pentosaceus* CECT8330/ KABP041®	Gouttes	1mds/5 gouttes	5 gouttes					I (144)						
FlorastorKids®	*Saccharomyces boulardii lyo* CNCM I-745	Capsule Sachet	5mds/ capsule 5mds/sachet	1-2 capsules 1-2 sachets	I (150)	III (151)					I (45,152)		I (147-149)		
HMF Baby Drops	*B. longum* CECT7894/ KABP042® *P. pentosaceus* CECT8330/ KABP041®	Gouttes	1mds/5 gouttes	5 gouttes					I (144)						
HMF Fit for School *[50 mg vitamine C, 1000UI vitamine D]*	*L. acidophilus* CUL-60 *L. acidophilus* CUL-21 *B. animalis subsp. lactis* CUL-34 *B. bifidum* CUL-20	Comp. à mâcher Poudre	12,5mds/ comp. à mâcher 12,5mds/ grosse mesure *(1 gramme)*	1 comp. à mâcher 1 mesure				I (153)							
MetaKids™ Baby Probiotic	*L. rhamnosus* GG *B. lactis* BB-12	Gouttes	1mds/6 gouttes	6 gouttes			II (155)	II (154)							
MetaKids™ Probiotic	*L. acidophilus* NCFM® *B. animalis subsp lactis* Bi-07®	Comp. à mâcher	5mds/comp. à mâcher	2 comp.s à mâcher				I (156)							

- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Produits probiotiques pour **la population pédiatrique :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	EI/DA	MIC	Coliques	MICI-CU	SCI	DI	SF	NEC
Orange Naturals Baby Probiotics +D3 Drops *(400IU)*	*L. rhamnosus* GG *B. lactis* BB12	Gouttes	2mds/5 gouttes	5 gouttes	II (155)	II (154)						
Orange Naturals Probiotics Kids Chewable + Vitamin A,C,D3	*L. acidophilus* NCFM *B. animalis subsp lactis* Bi-07	Comp. à mâcher	5mds/comp. à mâcher	1 comp. à mâcher		I (156)						
ProZema®	*B. lactis* BPL1 CECT 8145 *B. longum* ES1 CECT 7347 *L. casei* BPL4 CECT 9104	Sachet de la poudre	1.55mds/ sachet	1 sachet	I (160-161)							
Probiotic Baby	*B. lactis* BB-12	Gouttes	1mds/6 gouttes	6 gouttes		I (162)	I (163)					
Purica Probiotic Baby Colic	*B. longum* CECT7894/KABP042® *P. pentosaceus* CECT8330/ KABP041®	Gouttes	1mds/5 gouttes	5 gouttes			I (144)					
Renew Life® FloraBaby	*B. breve* HA-129 *L. rhamnosus* HA-111 *B. bifidum* HA-132 *B. infantis* HA-116 *B. longum* HA-135	Poudre	2mds/mesure	1-2 mesures								II (145-146)
Sisu Probiotic Kid Stiks	*L. helveticus* R0052 *B. infantis* R0033 *B. bifidum* R0071	Sachet de la poudre	5mds/sachet	1 sachet		I (164-165)						
Visbiome® *Cette combinaison de souches est connue sous le nom de la formulation du prof. De Simone et est la même que celle mentionnée dans les références qui citent VSL #3 comme schéma thérapeutique*	*L. acidophilus* DSM24735/SD5212 *L. paracasei* DSM24733/SD5218 *L. delbrueckii subsp. bulgaricus* DSM24734/SD5210 *L. plantarum* DSM24730/SD5209 *B. longum* DSM24736/SD5220 *B. infantis* DSM24737/SD5219 *B. breve* DSM24732/SD5206 *S. thermophilus* DSM24731/SD5207	Sachet	450mds/ sachet	1-2 sachets				I (167-168)	I (169)	I (166)	I (170)	

- Le produit nécessite une réfrigération
- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Produits probiotiques pour **la santé maternelle et vaginale :**

Marque de commerce	Souche(s) de probiotiques	Préparation	UFC/dose	Nombre de doses par jour	VB	Mastite	CV
Materna® Opti-Lac® Breast Feeding Support	*L. fermentum* LC40™ CECT5716	Capsule	3mds/capsule	1 capsule		I (55-56)	
Probaclac BV®	*L. acidophilus* A-212 *L. rhamnosus* A-119 *S. thermophilus* A-336	Capsule vaginale	8mds/capsule	1-2 capsules	II (179)		
Provacare®	*L. rhamnosus* Lcr35	Ovule vaginale	3.41mds/ovule	2 ovules	I (181-183)		I (180)
RepHresh™ Pro-B™ Probiotic	*L. rhamnosus* GR-1 *L. reuteri* RC-14	Capsule orale	0.5mds chaque/ capsule	2-4 capsules	I (171,173-175,177-178)		I (172,175-176)
UltraFlora® Women's	*L. reuteri* RC-14 *L. rhamnosus* GR-1	Capsule orale	1mds chaque/ capsule	2 capsules	I (171,173-175,177-178)		I (172,175-176)

- Le produit nécessite une réfrigération
- Approuvé par Santé Canada pour l'indication énumérée; applicable aux suppléments
- Sans gluten

Aliments fonctionnels avec des probiotiques ajoutés (Adultes) :

Marque de commerce	Souche(s) de probiotiques	UFC/dose	Nombre de doses par jour	DAA	C	DACD	MIC	SCI	H/A
Activia® ❄	*B. (animalis) lactis* CNCM I-2494	1mds/portion	1-3 portions		I (186)			I (184-185)	
DanActive® ❄	*L. casei sp. paracasei* CNCM I-1518	10mds/portion	1-2 portions	I (191,202)			I (194-201)		
GoodBelly® Probiotic Juice Drinks	*L. plantarum* 299v	20mds/portion (8oz)	1 portion	III (31)		III (32,36)		I (33-35)	
Yakult ❄	*L. casei* Shirota	8mds/bouteille (80mL)	1-2 bouteilles		I (209-210)		I (211-214)		II (215-216)

Aliments fonctionnels avec des probiotiques ajoutés (Enfants) :

Marque de commerce	Souche(s) de probiotiques	UFC/dose	Nombre de doses par jour	DAA	MIC	APLV	HP	DI
DanActive® ❄	*L. casei sp. paracasei* CNCM I-1518	10mds/portion	1-2 portions		I (190,192-193)		I (189)	II (187-188)
Céréales pour bébés Gerber®	*B. lactis* BB-12	1mds/portion *[portion=5 tbls]*	1 portion	I (204)	I (162,203)			
Céréales pour toutpetits Gerber® *(12 mois et plus)*		1mds/portion *[portion=5 tbls]*	1 portion					
Bien GrandirMC Tout-Petits *(supplément nutritionnel)*		1mds/portion de 200mL	1 portion					
Bon Départ® Soothe™	*L. reuteri* DSM 17938	1mns/gramme	Pour l'alimentation régulière si l'utilisation d'un substitut au lait maternel est nécessaire					I (102-106)
Bon Départ® Plus 1	*B. lactis* BB-12	1mns/gramme	Pour l'alimentation régulière si l'utilisation d'un substitut au lait maternel est nécessaire		I (162,203)			
Bon Départ® Plus 2 *(6 mois et plus)*		130mns/portion de 100mL	Pour l'alimentation régulière si l'utilisation d'un substitut au lait maternel est nécessaire	I (204)	I (162,203)			
Nestlé® Nido® *(supplément nutritionnel)*	*B. lactis* BB-12	1mds/portion de 200mL	1 portion	I (204)	I (162,203)			
Nutramigen® A+® avec LGG® *Préparation à base de caséine fortement hydrolysée (PCFH)*	*L. rhamnosus* GG [Branded LGG]	1.35 × 10^7 UFC /portion de 100mL	PCFH quand une alternative au lait maternel est nécessaire			I (205-208)		

❄ - **Le produit nécessite une réfrigération**

Références :

1. Brenner, DM, and WD Chey. "Bifidobacterium Infantis 35624: A Novel Probiotic for the Treatment of IBS." Reviews in Gastroenterological Disorders 9.1 (2009): 7-15.
2. Quigley, EM, PJ Whorwell, L. Altringer, J. Morel, L. O'Mahony, and F. Shanahan. "Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacterium Infantis 35624." American Journal of Gastroenterology 100.S9 (2005): S326.
3. Whorwell, P., L. Altringer, J. Morel, Y. Bond, D. Charbonneau, L. O'Mahony, B. Kiely, F. Shanahan, and EM Quigley. "Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome." American Journal of Gastroenterology 101 (2006): 1581-590.
4. O'Mahony, L., J. Mccarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O'Sullivan, B. Kiely, J. K. Collins, F. Shanahan, and E. M. Quigley. "Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles." Gastroenterology 128.3 (2005): 541-51.
5. Beausoleil, M., N. Fortier, S. Guenette, A. L'Ecuyer, M. Savoie, M. Franco, J. Lachaine, and K. Weiss. "Effect of a Fermented Milk Combining Lactobacillus Acidophilus CL1285 And Lactobacillus Caseiin the Prevention of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial." Canadian Journal of Gastroenterology 21.11 (2007): 732-36.
6. Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. "Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium Difficile-Associated Diarrhea Prophylaxis in Adult Patients." American Journal of Gastroenterology 105.7 (2010): 1636-641.
7. Sampalis, J., E. Psaradellis, and E. Rampakakis. "Efficacy of BIO K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea – a Placebo Controlled Double-Blind Randomized, Multi-Center Study." Archives of Medical Science: AMS 6.1 (2010): 56–64.
8. Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. "Probiotics for the Prevention of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis." Annals of Internal Medicine 157.12 (2012): 878
9. Johnson, S., P.J Maziade, L. V. McFarland, W. Trick, C. Donskey, B. Currie, D. E. Low, and E. J.C Goldstein. "Is Primary Prevention of Clostridium Difficile Infection Possible with Specific Probiotics?" International Journal of Infectious Diseases 6.11 (2012): E786-792.
10. McFarland, L.V., N. Ship, J. Auclair and M. Millette. "Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence " Journal of Hospital Infection 99.4 (2018):443-452.
11. Aiello, R. A., M. Ali, M. Chiarenza, G. Carillio, G. Scandurra, and M. Caruso. "Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhoea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule." Annals of Oncology. S9 ed. Vol. 19. (2008).
12. Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. "A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults." Journal of Clinical Gastroenterology 45.9 (2011): 785-89.
13. Ainora, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.l. Novi, D. Roccarina, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. "Pa.29 Impact Of L. Reuterii Supplementation On Anti-H. Pylori Second Line Therapy-Related." Digestive and Liver Disease 40 (2008)
14. Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogiovanni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Miniello. "Inhibition of Helicobacter Pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study." Helicobacter 13.2 (2008): 127-34.
15. Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. "Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection--a Double-blind Randomised Placebo-controlled Cross-over Clinical Study." Journal of the Japanese Association for Infectious Diseases 81.4 (2007): 387-93.
16. Saggioro, A., M. Caroli, M. Pasini, F. Bortoluzzi, L. Girardi, and G. Pilone. "Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study." Dig Liver Dis 37.Suppl 1 (2005): S88.
17. Ojetti, V., G. Ianiro, A. Tortora, G. D'Angelo, T. A. Di Rienzo, S. Bibbo, A. Migneco, and A. Gasbarrini. "The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial."Journal of Gastrointestinal and Liver Diseases 23.4 (2014): 387-91.
18. Preston, K., R. Krumian, J. Hattner, D. de Montigny, M. Stewart and S. Gaddam. "Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study." Beneficial Microbes 9.5 (2018): 697-706.
19. Majeed, Muhammed et al.: "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study." Nutrition journal vol. 15 21. 27 Feb. 2016, doi:10.1186/s12937-016-0140-6
20. Huang R., H. Ning, L. Yang, C. Jia, F. Yang, G. Xu, and H. Tan. "Efficacy of Probiotics on Anxiety: A Meta-analysis of Randomized Controlled Trials." Neuropsychiatry 7.6 (2017): 862-71.
21. Messaoudi M., R. Lalonde, N. Violle, H. Javelot, D. Desor, A. Nejdi, J. Bisson, C. Rougeot, M. Pichelin, M. Cazaubiel, and J. Cazaubiel. "Assessment of Psychotropic-like Properties of a Probiotic Formulation (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) in Rats and Human Subjects." British Journal of Nutrition 105.05 (2010): 755-64.
22. Messaoudi M., N.Violle, J. Bisson, D. Desor, H. Javelot, and C. Rougeot. "Beneficial Psychological Effects of a Probiotic Formulation (Lactobacillus HelveticusR0052 AndBifidobacterium LongumR0175) in Healthy Human Volunteers." Gut Microbes 2.4 (2011): 256-61.
23. Kale-Pradhan, P. B., H. K. Jassal, and S. M. Wilhelm. "Role of Lactobacillus in the Prevention of Antibiotic-Associated Diarrhea: A Meta-analysis." Pharmacotherapy 30.2 (2010): 119-26.
24. Armuzzi, A., F. Cremonini, F. Bartolozzi, F. Canducci, M. Candelli, V. Ojetti, G. Cammarota, M. Anti, A. De Lorenzo, P. Pola, G. Gasbarrini, and A. Gasbarrini. "The Effect of Oral Administration of Lactobacillus GG on Antibiotic-associated Gastrointestinal Side-effects during Helicobacter Pylori Eradication Therapy." Alimentary Pharmacology and Therapeutics 15.2 (2001): 163-69.
25. Gorbach, S. L., Chang, T. W. & Goldin, B. "Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG." Lancet 2, 1519 (1987).
26. Bennet RG, Gorbach SL et al. "Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG" Nutr Today Suppl Vol 31 No 6 Nov/Dec 1996
27. Morrow, L. E., Kollef, M. H. & Casale, T. B. "Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial." American journal of respiratory and critical care medicine 182, 1058-1064 (2010).
28. Gosselink MP, Schouten WR et al. "Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG" Dis Colon Rectum 2004; 47: 876-84
29. Oksanen, P.J., et al. "Prevention of travellers' diarrhoea by Lactobacillus GG." Annals of medicine, 1990. 22(1): p. 53-56.
30. Hilton, E., et al. "Efficacy of Lactobacillus GG as a diarrheal preventive in travelers." Journal of travel medicine, 1997. 4(1): p. 41-43.
31. Lonnermark, E., V. Friman, G. Lappas, T. Sandberg, A. Berggren, and I. Adlerberth. "Intake of Lactobacillus Plantarum Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics." Journal of Clinical Gastroenterology 44.2 (2010): 106-12.
32. Klarin, B., M. Wullt, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. "Lactobacillus Plantarum 299v Reduces Colonisation of Clostridium Difficile in Critically Ill Patients Treated with Antibiotics." Acta Anaesthesiologica Scandinavica 52.8 (2008): 1096-102.
33. Niedzielin, K., H. Kordecki, and B. Birkenfeld. "A Controlled, Double-blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome." European Journal of Gastroenterology and Hepatology 13.10 (2001): 1143-147.
34. Nobaek, S., M. L. Johansson, G. Molin, S. Ahrne, and B. Jeppsson. "Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome." The American Journal of Gastroenterology 95.5 (2000): 1231-238.
35. Ducrotte, P., P. D. Sawant, and V. Jayanthi. "Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome." World Journal of Gastroenterology 18.30 (2012): 4012-018.
36. Kujawa-Szewieczek, A.; Adamczak, M.; Kwiecień, K.; Dudzicz, S.; Gazda, M.; Więcek, A. "The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics." Nutrients 2015, 7, 10179-10188
37. Can, M., B. A. Besirbellioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. "Prophylactic Saccharomyces Boulardii in the Prevention of Antibiotic-associated Diarrhea: A Prospective Study." Medical Science Monitor 12.4 (2006): PI19-22.
38. Surawicz, C. M., L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. "The Search for a Better Treatment for RecurrentClostridium DifficileDisease: Use of High Dose Vancomycin Combined WithSaccharomyces Boulardii." Clinical Infectious Diseases 31.4 (2000): 1012-017.
39. Mcfarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. "A Randomized Placebo-controlled Trial of Saccharomyces Boulardii in Combination with Standard Antibiotics for Clostridium Difficile Disease." JAMA: The Journal of the American Medical Association 271.24 (1994): 1913-918.
40. Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneider. "Prevention of traveller's diarrhea: comparison of different non-antibiotic preparations." Travel Med Int 11 (1989): 9-17.
41. Kollaritsch, H., H. Holst, P. Grobara, and G. Wiedermann. "Prophylaxis of traveller's diarrhoea with Saccharomyces boulardii." Fortschr Med 111 (1993): 152-156. (Article in German)

42 McFarland, L. V. "Meta-analysis of probiotics for the prevention of traveler's diarrhea." Travel medicine and infectious disease 5.2 (2007): 97-105.

43 Guslandi, M., G. Mezzi, M. Sorghi, and P.A. Testoni. "Saccharomyces boulardii in maintenance treatment of Crohn's disease." Digestive diseases and sciences 45.7 (2000): 1462-1464.

44 Song, M. J., D.I Park, J.H. Park, H.J. Kim, Y.K. Cho, C.I. Sohn, W.K. Jeon, and B.I. Kim. "The Effect of Probiotics and Mucoprotective Agents on PPI-Based Triple Therapy for Eradication of Helicobacter pylori." Helicobacter 15.3 (2010): 206-213.

45 Szajewska, H., A. Horvath, and A. Piwowarczyk. "Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment." Alimentary pharmacology & therapeutics 32.9 (2010): 1069-1079.

46 Cindoruk, M., G. Erkan,T. Karakan, A. Dursun, and S. Unal. "Efficacy and Safety of Saccharomyces boulardii in the 14-day Triple Anti-Helicobacter pylori Therapy: A Prospective Randomized Placebo-Controlled Double-Blind Study." Helicobacter 12.4 (2007): 309-316.

47 Guslandi, M., Giollo, P., and Testoni, P. "(2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis." European Journal Of Gastroenterology And Hepatology 15, 697-698.

48 Sivananthan, K., and Petersen, A. "(2018). Review of Saccharomyces boulardii as a treatment option in IBD." Immunopharmacology And Immunotoxicology 40, 465-475.

49 Tang, H., Wu, H., Mao, J., Zhu, L., Li, N., and Wang, Y. "(2014). Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis." 11Th IEEE International Conference On Control And Automation (ICCA).

50 Zhou, W. "(2017). Saccharomyces boulardii powder combined with mesalazine for treatment of active ulcerative colitis: Curative effect and impact on fecal calprotectin and serum inflammatory factors." World Chinese Journal Of Digestology 25, 2065.

51 Flatley EA, Wilde AM, Nailor MD. "Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection." J Gastrointestin Liver Dis. 2015;24(1):21–24

52 Plummer, S., M.A. Weaver, J.C. Harris,P. Dee, and J. Hunter. "Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea." International Microbiology 7.1 (2010): 59-62.

53 Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. "Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study." Alimentary pharmacology & therapeutics 29.1 (2009): 97-103.

54 Michael, D.R., Jack, A.A., Masetti, G. et al. "A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being." Sci Rep 10, 4183 (2020). https://doi.org/10.1038/s41598-020-60991-7

55 Maldonado-Lobón, Jose A et al. "Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial." Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine vol. 10,9 (2015): 425-32.

56 Arroyo, Rebeca et al. "Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 50,12 (2010): 1551-8. doi:10.1086/652763

57 Floch, Martin H. "Probiotic therapy for ulcerative colitis." Journal of clinical gastroenterology 44.4 (2010): 237-238.

58 Henker, J., S. Müller, M.W Laass, A. Schreiner, and J. Schulze. "Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study." Zeitschrift fuer Gastroenterologie 46.09 (2008): 874-875.

59 Kruis, W., E. Schütz, P. Fric, B. Fixa, G. Judmaier, and M. Stolte. "Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis." Alimentary pharmacology & therapeutics 11.5 (1997): 853-858.

60 Kruis, W., P. Frič, J. Pokrotnieks, M. Lukáš, B. Fixa, M. Kaščák, M.A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, and C. Wolff. "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine." Gut 53.11 (2004): 1617-1623.

61 Burton, J. P., C. N. Chilcott, C. J. Moore, G. Speiser, and J. R. Tagg.. "A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters." Journal of applied microbiology 100.4 (2006): 754-764.

62 Di Pierro, F, G. Donato, F. Fomia, T. Adami, D. Careddu, C. Cassandro, and R. Albera. "Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media." International journal of general medicine 5 (2012): 991.

63 Schlagenhauf U, Jakob L et al. "Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT." J Clin Periodontol. 2016 Nov;43(11):948-954

64 Teughels W, Durukan A, et al. "Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study." J Clin Periodontol 2013; 40: 1025–1035

65 Galofré M, Palao D, Vicario M, Nart J, Violant D. "Clinical and microbiological evaluation of the effect of Lactobacillus reuteri in the treatment of mucositis and peri-implantitis: A triple-blind randomized clinical trial." J Periodontal Res. 2018 Jun;53(3):378-390.

66 Kraft-Bodi E, Jørgensen M, Keller MK. "Effect of Probiotic Bacteria on Oral Candida in Frail Elderly." J Dent Res. 2015 Sep;94(9 Suppl):181S-6S

67 Tekce M, Ince G, Gursoy H, et al. "Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study." J Clin Periodontol 2015; 42: 363–372

68 Agraib, Lana M et al. "Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study." Clinical nutrition ESPEN vol. 51 (2022): 83-91. doi:10.1016/j.clnesp.2022.08.020

69 Benes, K., A. Kretk, and Thomas A. Tompkins. "A probiotic combination for IBS. A pilot clinical study." NutraFoods 5.1 (2006): 20-27.

70 Fuentes, Mari C et al. "Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults." The British journal of nutrition vol. 109,10 (2013): 1866-72.

71 Kerlikowsky F, Greupner T, Müller M, Mazo JE, Müller HJ, Hahn A. Probiotic formulation influences blood cholesterol levels: a randomized, controlled trial during the covid19 pandemic. Clin Nutr ESPEN. 2021

72 Fuentes, Mari C., et al. "A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol." Mediterranean Journal of Nutrition and Metabolism 9.2 (2016): 125-135.

73 Lorenzo-Zúñiga, Vicente et al. "I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life." World journal of gastroenterology vol. 20,26 (2014): 8709-16.

74 Barraza-Ortiz, Diego A et al. "Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study." Digestive diseases (Basel, Switzerland) vol. 39,3 (2021): 294-300. doi:10.1159/000510950

75 A.C. Ouwehand et al. "Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study." Vaccine 32 (2014) 458–463

76 Engelbrektson A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL. "Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy." J Med Microbiol. 2009 May;58(Pt 5):663-670. doi: 10.1099/jmm.0.47615-0. PMID: 19369530.

77 Stenman L. K., Lehtinen M.J., Meland N., Christensen J.E., Yeung N., Saarinen M.T.,Courtney M., Burcelin R., Lähdeaho M., Linros J., Apter D., Scheinin M., Kloster Smerud H, Rissanen A., and Lahtinen S.. "Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial." EBioMedicine 13 (2016): 190-200.

78 Ringel-Kulka T, Palsson OS, Maier D, et al. "Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders." Journal of Clinical Gastroenterology. 2011;45(6):518–525

79 Berggren, A., I. L. Ahrén, N. Larsson, and G. Önning. "Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections." European journal of nutrition 50.3 (2011): 203-210.

80 Regina, B., G. Joerg, and D. Steffi. "Randomized, Double Blind and Placebo Controlled Study Using a Combination of Two Probiotic Lactobacilli to Alleviate Symptoms and Frequency of Common Cold." Food and Nutrition Sciences 2013 (2013).

81 Parkes, G. C., D. Chatoor, and A. Emmanuel. "The probiotic VSL# 3 increases scbm and reduces symptom severity scores in patients with functional constipation." Gut 60.Suppl 1 (2011): A163-A163

82 Sood, A., V. Midha, G.K. Makharia, V. Ahuja, D. Singal, P. Goswami, and R.K. Tandon. "The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis." Clinical Gastroenterology and Hepatology 7.11 (2009): 1202-1209.

83 Tursi, A., G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo, and A. Gigliobianco. "Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis." Medical Science Monitor 10.11 (2004): PI126-PI131.

84 Tursi, A., G. Brandimarte, A. Papa, A. Giglio, W. Elisei, G.M. Giorgetti, G. Forti, S. Morini, C. Hassan, M.A. Pistoia, and M.E. Modeo. "Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study." The American Journal of Gastroenterology 105.10 (2010): 2218-2227.

85 Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli, and M. Campieri."Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial." Gastroenterology 119.2 (2000): 305-309.

86 Gionchetti, P., F. Rizzello, U. Helwig, A. Venturi, K. M. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli, and M. Campieri. "Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial." Gastroenterology 124.5 (2003): 1202-1209.

87 Mimura, T., F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I. C. Talbot, R. J. Nicholls, P. Gionchetti, M. Campieri, and M. A. Kamm. "Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis." Gut 53.1 (2004): 108-114.

88 Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol. 2012;107:1043–1050.

89 Shukla S., Shukla A., Mehboob S., et al. "Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy." Alimen Pharmacol Ther. 2011;33:662–671.

90 Mittal, V.V. et al. "A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy." European Journal of Gastroenterology and Hepatology. 2011, 23:725–732

91 Lunia, M.K. et al."Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial." Clinical Gastroenterology and Hepatology. 2014 Jun;12(6):1003-8

92 Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, Jung KW, Koo HS, Myung SJ "Constipation Research group of Korean Society of Neurogastroenterology and Motility. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation." J Neurogastroenterol Motil. 2015 Jan 1;21(1):111-20. doi: 10.5056/jnm14048. PMID: 25537674; PMCID: PMC4288088.

93 Duseja, Ajay et al.: "High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study." BMJ open gastroenterology vol. 6,1 e000315. 7 Aug. 2019, doi:10.1136/bmjgast-2019-000315

94 Román, Eva et al.: "Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial." Hepatology communications vol. 3,5 632-645. 12 Mar. 2019, doi:10.1002/hep4.1325

95 Indrio, F., G. Riezzo, F. Raimondi, M. Bisceglia, L. Cavallo, and R. Francavilla. "The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns." The Journal of pediatrics 152.6 (2008): 801-806.

96 Indrio, F., G. Riezzo, F. Raimondi, M. Bisceglia, A. Filannino, L. Cavallo, and R. Francavilla. "Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants." European journal of clinical investigation 41.4 (2011): 417-422.

97 Garofoli, F., E. Civardi, F. Indrio, I. Mazzucchelli, M. Angelini, C. Tinelli, and M. Stronati. "The early administration of Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants." International journal of food sciences and nutrition 65.5 (2014): 646-648.

98 Savino, F., E. Pelle, E. Palumeri, R. Oggero, and R. Miniero. "Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study." Pediatrics 119.1 (2007): e124-e130.

99 Savino, F., L. Cordisco, V. Tarasco, E. Palumeri, R. Calabrese, R. Oggero, S. Roos, and D. Matteuzzi. "Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial." Pediatrics 126.3 (2010): e526-e533.

100 Sung, V., H. Hiscock, M.L.K. Tang, F.K. Mensah, M.L. Nation, C. Satzke, R.G. Heine, A. Stock, R.G. Barr, and M. Wake. "Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial." BMJ 348 (2014): g2107.

101 Chau, K., E. Lau, S. Greenberg, S. Jacobson, P. Yazdani-Brojeni, N. Verma, and G. Koren. "Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938." The Journal of pediatrics 166.1 (2015): 74-78.

102 Eom, T.H., E.Y. Oh, Y.H. Kim, H.S. Lee, P.S. Jang, D.U. Kim, J.T. Kim, and B.C. Lee."The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers." Korean Journal of Pediatrics 48.9 (2005): 986-990.

103 Shornikova, A.V., I.A. Casas, E. Isolauri, H. Mykkänen, and T. Vesikari. "Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children." Journal of pediatric gastroenterology and nutrition 24.4 (1997): 399-404.

104 Agustina, R, F.J. Kok, O. van de Rest, U. Fahmida, A. Firmansyah, W. Lukito, E.J.M Feskens, E.G.H.M van den Heuvel, R. Albers, and I.M.J. Bovee-Oudenhoven. "Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children." Pediatrics 129.5 (2012): e1155-e1164.

105 Francavilla, R., E. Lionetti, S. Castellaneta, F. Ciruzzi, F. Indrio, A. Masciale, C. Fontana, M. M. La Rosa, L. Cavallo, and A. Francavilla. "Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea-a double-blind study." Alimentary pharmacology & therapeutics 36.4 (2012): 363-369.

106 Dinleyici, E.C., and Y. Vandenplas. "Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children." Acta Paediatrica 103.7 (2014): e300-e305.

107 Lionetti, E., V. L. Miniello, S. P. Castellaneta, A. M. Magista, A. De Canio, G. Maurogiovanni, E. Ierardi, L. Cavallo, and R. Francavilla. "Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial." Alimentary pharmacology & therapeutics 24.10 (2006): 1461-1468.

108 Coccorullo, P., C. Strisciuglio, M. Martinelli, E. Miele, L. Greco, and A. Staiano."Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study." The Journal of pediatrics 157.4 (2010): 598-602.

109 Indrio, F., A. Di Mauro, G. Riezzo, E. Civardi, C. Intini, L. Corvaglia, E. Ballardini, M. Bisceglia, M. Cinquetti, E. Brazzoduro, and A. Del Vecchio. "Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial." JAMA pediatrics 168.3 (2014): 228-233.

110 Romano, C., V. Ferrau, F. Cavataio, G. Iacono, M. Spina, E. Lionetti, F. Comisi, A. Famiani, and D. Comito."Lactobacillus reuteri in children with functional abdominal pain (FAP)." Journal of paediatrics and child health 50.10 (2014): E68-E71.

111 Weizman, Z. "A Randomized Controlled Trial of Lactobacillus reuteri DSM 17938 in Functional abdominal pain of childhood." SP-N-0102, Nutrition Trial symposia within the ESPGHAN program (9-12th of June, 2014 presented at 47th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, in Jerusalem).

112 Weizman, Z., G. Asli, and A. Alsheikh. "Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents." Pediatrics 115.1 (2005): 5-9.

113 Gutierrez-Castrellon, P., G. Lopez-Velazquez, L. Diaz-Garcia, C. Jimenez-Gutierrez, J. Mancilla-Ramirez, J. Estevez-Jimenez, and M. Parra. "Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial." Pediatrics 133.4 (2014): e904-e909.

114 Abrahamsson, T.R., T. Jakobsson, M.F. Böttcher, M. Fredrikson, M.C. Jenmalm, B. Björkstén, and G. Oldaeus. "Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial." Journal of Allergy and Clinical Immunology 119.5 (2007): 1174-1180.

115 Forsberg et al. "Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants" Clinical and Translational Allergy 2014, 4:21

116 Mi GL, Zhao L et al. "Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial." Antonie Van Leeuwenhoek. 2015 Jun;107(6):1547-53.

117 Szajewska, Hania, et al. "Lactobacillus Reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A Randomized, Double-Blind, Placebo-Controlled Trial." The Journal of Pediatrics, vol. 162, no. 2, Feb. 2013, pp. 257–262, doi:10.1016/j.jpeds.2012.08.004.

118 Hunter, C., M.V.T Dimaguila, P. Gal, J.E. Wimmer, J.L. Ransom, R.Q. Carlos, M. Smith, and C.C. Davanzo. "Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight< 1000 grams: a sequential analysis." BMC pediatrics 12.1 (2012): 1.

119 Athalye-Jape, Gayatri, et al. "Lactobacillus Reuteri DSM 17938 as a Probiotic for Preterm Neonates : A Strain-Specific Systematic Review." Journal of Parenteral and Enteral Nutrition, vol. 40, no. 6, Aug. 2016, pp. 783–794, doi:10.1177/0148607115588113.

120 Dimaguila M, Gal P, Wilson T, Wimmer Jr J, Smith Mc, Carlos R, Davanzo C, Ransom J. "Pharmacoeconomic impact of use of the probiotic Lactobacillus reuteri DSM 17938 for prevention of necrotizing enterocolitis in extremely low-birth-weight infants." Research and Reports in Neonatology. 2013;3:21-25 https://doi.org/10.2147/RRN.S43272

121 Szajewska, H., and J.Z. Mrukowicz. "Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials." Journal of pediatric gastroenterology and nutrition 33 (2001): S17-S25.

122 Basu, S., M. Chatterjee, S. Ganguly, and P.K. Chandra. "Efficacy of Lactobacillus rhamnosus GG in acute watery diarrhoea of Indian children: a randomised controlled trial." Journal of paediatrics and child health 43.12 (2007): 837-842.

123 Basu, S., D.K. Paul, S. Ganguly, M. Chatterjee, and P.K. Chandra. "Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial." Journal of clinical gastroenterology 43.3 (2009): 208-213.

124 Guandalini, S., L. Pensabene, M.A. Zikri, J.A Dias, L.G. Casali, H. Hoekstra, S. Kolacek, K. Massar, D. Micetic–Turk, A. Papadopoulou, and J.S. de Sousa. "Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial." Journal of pediatric gastroenterology and nutrition 30.1 (2000): 54-60.

125 Ritchie, B.K., D.R. Brewster, C.D. Tran, G.P. Davidson, Y. McNeil, and R.N. Butler. "Efficacy of Lactobacillus GG in aboriginal children with acute diarrhoeal disease: a randomised clinical trial." Journal of pediatric gastroenterology and nutrition 50.6 (2010): 619-624.

126 Misra, S., T.K. Sabui, and N.K. Pal. "A randomized controlled trial to evaluate the efficacy of lactobacillus GG in infantile diarrhea." The Journal of pediatrics 155.1 (2009): 129-132.

127 Vanderhoof, J.A., D.B. Whitney, D.L. Antonson, T.L. Hanner, J.V. Lupo, and R.J. Young."Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children." The Journal of pediatrics 135.5 (1999): 564-568.

128 Johnston, B.C., J.Z. Goldenberg, P.O. Vandvik, X. Sun, and G.H. Guyatt. "Probiotics for the prevention of pediatric antibiotic-associated diarrhea." The Cochrane Library (2011).

129 Gawrońska, A., P. Dziechciarz, A. Horvath, and H. Szajewska. "A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children." Alimentary pharmacology & therapeutics 25.2 (2007): 177-184.

130 Francavilla R., V. Miniello, A.M. Magistà, A. De Canio, N. Bucci, F. Gagliardi, E. Lionetti, S. Castellaneta, L. Polimeno, L. Peccarisi, and F. Indrio. "A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain." Pediatrics 126.6 (2010): e1445-e1452.

129 Gawrońska, A., P. Dziechciarz, A. Horvath, and H. Szajewska. "A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children." Alimentary pharmacology & therapeutics 25.2 (2007): 177-184.

130 Francavilla R., V. Miniello, A.M. Magistà, A. De Canio, N. Bucci, F. Gagliardi, E. Lionetti, S. Castellaneta, L. Polimeno, L. Peccarisi, and F. Indrio. "A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain." Pediatrics 126.6 (2010): e1445-e1452.

131 Hojsak, I., S. Abdović, H. Szajewska, M. Milošević, Ž. Krznarić, and S. Kolaček. "Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections." Pediatrics 125.5 (2010): e1171-e1177.

132 Doege, K., D. Grajecki, B.C. Zyriax, E. Detinkina, C. zu Eulenburg, and K.J. Buhling."Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood–a meta-analysis." British journal of nutrition 107.01 (2012): 1-6.

133 Kalliomäki, M., S. Salminen, H. Arvilommi, P. Kero, P. Koskinen, and E. Isolauri "Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial." The Lancet 357.9262 (2001): 1076-1079.

134 Rautava, S., M. Kalliomäki, and E. Isolauri. "Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant." Journal of Allergy and Clinical Immunology 109.1 (2002): 119-121.

135 Kalliomäki, M., S. Salminen, T. Poussa, H. Arvilommi, and E. Isolauri. "Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial." The Lancet 361.9372 (2003): 1869-1871.

136 Kalliomäki, M., S. Salminen, T. Poussa, and E. Isolauri. "Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial." Journal of Allergy and Clinical Immunology 119.4 (2007): 1019-1021.

137 Dotterud, C. K., O. Storrø, R. Johnsen, and T. Øien. "Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial." British Journal of Dermatology 163.3 (2010): 616-623.

138 Boyle, R. J., I. H. Ismail, S. Kivivuori, P. V. Licciardi, R. M. Robins-Browne, L-J. Mah, C. Axelrad, S. Moore, S. Donath, J.B. Carlin, and S.J. Lahtinen. "Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial." Allergy 66.4 (2011): 509-516.

139 Lavekar, A.S., D.V. Raje, T. Manohar, and A.A. Lavekar. "Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis." Euroasian J Hepato-Gastroenterol 7.2 (2017): 130-37.

140 Vajro P., C. Mandato, M.R. Licenziati, A. Franzese, D.F. Vitale, S. Lenta, M. Caropreso, G.Vallone, and R.Meli. "Effects of Lactobacillus Rhamnosus Strain GG in Pediatric Obesity-related Liver Disease." Journal of Pediatric Gastroenterology and Nutrition 52.6 (2011): 740-43.

141 Szajewska H, Kolodziej M, et al. "Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children – a 2019 update." Aliment Pharmacol Ther. 2019;00:1–9.

142 Hojsak I, Snovak N et al. "Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: A randomized, double-blind, placebo-controlled trial" Clinical Nutrition 29 (2010) 312–316

143 Carucci, Laura et al. "Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial." Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology vol. 33,8 (2022): e13836. doi:10.1111/pai.13836

144 Chen, Ke et al. "Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial." Frontiers in pediatrics vol. 9 (2009) 635176.

145 Janvier, A., J. Malo, and K.J. Barrington. "Cohort study of probiotics in a North American neonatal intensive care unit." The Journal of pediatrics 164.5 (2014): 980-985.

146 Samara, Jumana et al. "Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants." Cell host & microbe vol. 30,5 (2022): 696-711.e5. doi:10.1016/j.chom.2022.04.005

147 Htwe, K., K.S. Yee, M. Tin, and Y. Vandenplas "Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study." The American journal of tropical medicine and hygiene 78.2 (2008): 214-216.

148 Kurugöl, Z., and G. Koturoğlu. "Effects of Saccharomyces boulardii in children with acute diarrhoea." Acta Paediatrica 94.1 (2005): 44-47.

149 Feizizadeh, S., A. Salehi-Abargouei, and V. Akbari. "Efficacy and safety of Saccharomyces boulardii for acute diarrhea." Pediatrics (2014): peds-2013.

150 Kotowska, M., P. Albrecht, and H. Szajewska. "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial." Alimentary pharmacology & therapeutics 21.5 (2005): 583-590.

151 Buts, J.P., G. Corthier, and M. Delmee. "Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants." Journal of pediatric gastroenterology and nutrition 16.4 (1993): 419-425.

152 Bin, Zhang, et al. "The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children." Pediatric gastroenterology, hepatology and nutrition 18.1 (2015): 17-22.

153 Garaiova, I., J. Muchová, Z. Nagyová, Duolao Wang, J. V. Li, Z. Országhová, D. R. Michael, S. F. Plummer, and Z. Ďuračková. "Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study." European journal of clinical nutrition 69.3 (2015): 373-379.

154 Rautava, S., S. Salminen, and E. Isolauri. "Specific probiotics in reducing the risk of acute infections in infancy–a randomised, double-blind, placebo-controlled study." British Journal of Nutrition 101.11 (2009): 1722-1726.

155 Schmidt RM, Pilmann Laursen R, Bruun S, et al. "Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial." Pediatr Allergy Immunol. 2019;00:1–6.

156 Leyer, G.J., S. Li, M.E. Mubasher, C. Reifer, and A.C. Ouwehand."Probiotic effects on cold and influenza-like symptom incidence and duration in children." Pediatrics 124.2 (2009): e172-e179.

157 Alamoudi, Najlaa M et al.: "Effect of Probiotic Lactobacillus reuteri on Salivary Cariogenic Bacterial Counts among Groups of Preschool Children in Jeddah, Saudi Arabia: A Randomized Clinical Trial." The Journal of clinical pediatric dentistry vol. 42,5 (2018): 331-338. doi:10.17796/1053-4625-42.5.2

158 Cannon, Mark et al.: "Effectiveness of CRT at measuring the salivary level of bacteria in caries prone children with probiotic therapy." The Journal of clinical pediatric dentistry vol. 38,1 (2013): 55-60. doi:10.17796/jcpd.38.1.b481624264142082

159 Maya-Barrios, A et al.: "Limosilactobacillus reuteri ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of pharyngitis/tonsillitis in children: randomised controlled trial." Beneficial microbes vol. 12,2 (2021): 137-145. doi:10.3920/BM2020.0171

160 Navarro-López, Vicente et al. "Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial." JAMA dermatology vol. 154,1 (2018): 37-43.

161 Tan-Lim, Carol Stephanie C et al. "Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis." Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 10.1111/pai.13305. 10 Jun. 2020, doi:10.1111/pai.13305

162 Taipale, T., K. Pienihäkkinen, E. Isolauri, C. Larsen, E. Brockmann, P. Alanen, J. Jokela, and E. Söderling. "Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy." British Journal of Nutrition 105.3 (2011): 409-416.

163 Nocerino et al. "The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial" Aliment Pharmacol Ther. 2019;00:1–11.

164 Cazzola, Mario et al.: "Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study." Therapeutic advances in respiratory disease vol. 4,5 (2010): 271-8. doi:10.1177/1753465810379010

165 Langkamp-Henken, Bobbi et al.: "Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study." The British journal of nutrition vol. 113,3 (2015): 426-34. doi:10.1017/S0007114514003997

166 Dubey, A.P., R. Krishnan, A. Chakravarti, A. Aggarwal, B.K. Atal, C. De Simone, V. Pandey, and A.R. Sahu. "W1772 Use of Vsl# 3®(a New High Concentration Probiotic Mixture) in the Treatment of Childhood Diarrhea with Specific Reference to Rotavirus Diarrhea." Gastroenterology 134.4 (2008): A-712.

167 Huynh, H.Q., J. deBruyn, L. Guan, H. Diaz, M. Li, S. Girgis, J. Turner, R. Fedorak, and K. Madsen. "Probiotic preparation VSL# 3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study." Inflammatory bowel diseases 15.5 (2009): 760-768.

168 Miele, E., F. Pascarella, E. Giannetti, L. Quaglietta, R.N. Baldassano, and A. Staiano. "Effect of a Probiotic Preparation (VSL# 3) on induction and maintenance of Remission in children with ulcerative colitis." The American journal of gastroenterology 104.2 (2009): 437-443.

169 Guandalini, S., G. Magazzu, A. Chiaro, V. La Balestra, G. Di Nardo, S. Gopalan, A. Sibal, C. Romano, R.B. Canani, P. Lionetti, and M. Setty. "VSL# 3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study." Journal of pediatric gastroenterology and nutrition 51.1 (2010): 24-30.

170 Alisi A., G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giammaria, L. Reali, F. Anania, and V. Nobili. "Randomised Clinical Trial: The Beneficial Effects of VSL#3 in Obese Children with Non-alcoholic Steatohepatitis." Alimentary Pharmacology & Therapeutics 39.11 (2014): 1276-285.

171 Anukam, K., E. Osazuwa, I. Ahonkhai, M. Ngwu, G. Osemene, A.W. Bruce, and G. Reid. "Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial." Microbes and Infection 8.6 (2006): 1450-1454.

172 Reid, G., D. Charbonneau, J. Erb, B. Kochanowski, D. Beuerman, R. Poehner, and A.W. Bruce. "Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women." FEMS Immunology & Medical Microbiology 35.2 (2003): 131-134.

173 Anukam, K.C., E. Osazuwa, G.I. Osemene, F. Ehigiagbe, A.W. Bruce, and G. Reid. "Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis." Microbes and Infection 8.12 (2006): 2772-2776.

174 Hummelen, R., J. Changalucha, N.L. Butamanya, A. Cook, J.D.F. Habbema, and G. Reid."Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV." International Journal of Gynecology & Obstetrics 111.3 (2010): 245-248.

175 Reid, G., A.W. Bruce, N. Fraser, C. Heinemann, J. Owen, and B. Henning. "Oral probiotics can resolve urogenital infections." FEMS Immunology & Medical Microbiology 30.1 (2001): 49-52.

176 Martinez, R.C., S. A. Franceschini, M. C. Patta, S. M. Quintana, R. C. Candido, J. C. Ferreira, E. C. P. De Martinis, and G. Reid. "Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14." Letters in applied microbiology 48.3 (2009): 269-274.

177 Martinez, R.C., S.A. Franceschini, M.C. Patta, S.M. Quintana, B.C. Gomes, E.C. De Martinis, and G. Reid. "Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial." Canadian journal of microbiology 55.2 (2009): 133-138.

178 Vujic, G., A.J. Knez, V.D. Stefanovic, and V.K. Vrbanovic. "Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study." European Journal of Obstetrics & Gynecology and Reproductive Biology 168.1 (2013): 75-79.

179 Ya, W., C. Reifer, and L.E. Miller. "Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study." American journal of obstetrics and gynecology 203.2 (2010): 120-e1.

180 Kern, A. M., J. M. Bohbot, and J. M. Cardot. "Preventive treatment of vulvovaginal candidosis with vaginal probiotic (gynophilus®-lcr regenerans®): Results of the observational study candiflore." La Lettre du Gynecologue 370 (2012): 33-7.

181 Marcone, V., G. Rocca, M. Lichtner, and E. Calzolari. "Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis." International Journal of Gynecology & Obstetrics 110.3 (2010): 223-226.

182 Petricevic, L., and A. Witt. "The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis." BJOG: An International Journal of Obstetrics & Gynaecology 115.11 (2008): 1369-1374.

183 Rossi, A., T. Rossi, M. Bertini, and G. Caccia. "The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months." Archives of gynecology and obstetrics 281.6 (2010): 1065-1069.

184 Agrawal, A., Lesley A. Houghton, J. Morris, B. Reilly, D. Guyonnet, N. Goupil Feuillerat, A. Schlumberger, S. Jakob, and P. J. Whorwell. "Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation." Alimentary pharmacology & therapeutics 29.1 (2009): 104-114.

185 Guyonnet, D., O. Chassany, P. Ducrotte, C. Picard, M. Mouret, C-H. Mercier, and C. Matuchansky. "Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial." Alimentary pharmacology & therapeutics 26.3 (2007): 475-486.

186 Yang, Y.X., M. He, G. Hu, J. Wei, P. Pages, X.H. Yang, and S. Bourdu-Naturel. "Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women." World J Gastroenterol 14.40 (2008): 6237-6243.

187 Pedone, C.A., A.O. Bernabeu, E.R. Postaire, C.F. Bouley, and P. Reinert. "The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres." International journal of clinical practice 53.3 (1998): 179-184.

188 Pedone, C.A., C.C. Arnaud, E.R. Postaire, C.F. Bouley, and P. Reinert. "Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea." International journal of clinical practice 54.9 (2000): 568-571.

189 Sýkora, J., K. Valecková, J. Amlerová, K. Siala, P. Dedek, S. Watkins, J. Varvarovská, F. Stožický, P. Pazdiora, and J. Schwarz. "Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study." Journal of clinical gastroenterology 39.8 (2005): 692-698.

190 Lin, J.S., Y.H. Chiu, N.T. Lin, C.H. Chu, K.C. Huang, K.W. Liao, and K.C. Peng. "Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study." Vaccine 27.7 (2009): 1073-1079.

191 Hickson, M., A.L. D'Souza, N. Muthu, T.R. Rogers, S. Want, C. Rajkumar, and C.J. Bulpitt. "Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial." Bmj 335.7610 (2007): 80.

192 Giovannini, M., C. Agostoni, E. Riva, F. Salvini, A. Ruscitto, G.V. Zuccotti, and G. Radaelli. "A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis." Pediatric research 62.2 (2007): 215-220.

193 Merenstein, D., M. Murphy, A. Fokar, R.K. Hernandez, H. Park, H. Nsouli, M.E. Sanders, B.A. Davis, V. Niborski, F. Tondu, and N.M. Shara. "Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial." European journal of clinical nutrition 64.7 (2010): 669-677.

194 Boge, T., M. Rémigy, S. Vaudaine, J. Tanguy, R. Bourdet-Sicard, and S. Van Der Werf. "A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials." Vaccine 27.41 (2009): 5677-5684.

195 Guillemard, E., F. Tondu, F. Lacoin, and J. Schrezenmeir. "Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial." British journal of nutrition 103.01 (2010): 58-68.

196 Guillemard, E., J. Tanguy, A.L. Flavigny, S. de la Motte, and J. Schrezenmeir. "Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial." Journal of the American College of Nutrition 29.5 (2010): 455-468.

197 Marcos, A., J. W., E. Nova, S. Gómez, A. Alvarez, R. Alvarez, J.A. Mateos, and J.M. Cobo. "The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress." European journal of nutrition 43.6 (2004): 381-389.

198 Meyer, A.L., M. Mickschе, I. Herbacek, and I. Elmadfa. "Daily intake of probiotic as well as conventional yogurt has a stimulating effect on cellular immunity in young healthy women." Annals of nutrition and metabolism 50.3 (2006): 282-289.

199 Ortiz-Andrellucchi, A., A. Sánchez-Villegas, C. Rodríguez-Gallego, A. Lemes, T. Molero, A. Soria, L. Pena-Quintana, M. Santana, O. Ramírez, J. García, and F. Cabrera. "Immunomodulatory effects of the intake of fermented milk with Lactobacillus casei DN114001 in lactating mothers and their children." British journal of nutrition 100.04 (2008): 834-845.

200 Tiollier, E., M. Chennaoui, D. Gomez-Merino, C. Drogou, E. Filaire, and C.Y. Guezennec. "Effect of a probiotics supplementation on respiratory infections and immune and hormonal parameters during intense military training." Military medicine 172.9 (2007): 1006-1011.

201 Turchet, P., M. Laurenzano, S. Auboiron, and J. M. Antoine. "Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study." The journal of nutrition, health & aging 7.2 (2002): 75-77.

202 Alberda C., S. Marcushamer, T. Hewer, N. Journault and D. Kutsogiannis "Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile." Nutrients. 2018 May; 10(5):539

203 Saavedra, J.M., A. Abi-Hanna, N. Moore, and R.H. Yolken. "Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety." The American journal of clinical nutrition 79.2 (2004): 261-267.

204 Corrêa, N.B., L.A. Péret Filho, F.J. Penna, F.M.S. Lima, and J.R. Nicoli. "A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants." Journal of clinical gastroenterology 39.5 (2005): 385-389.

205 Baldassarre M.E., Laforgia N., Fanelli M., Laneve A., Grosso R., and Lifschitz C. "Lactobacillus GG Improves Recovery in Infants with Blood in the Stools and Presumptive Allergic Colitis Compared with Extensively Hydrolyzed Formula Alone." The Journal of Pediatrics 156.3 (2010): 397-401.

206 Canani R.B., Nocerino R., Terrin G., Frediani T., Lucarelli S., Cosenza L., Passariello A., Leone L., Granata V., Di Costanzo M., Pezzella V., and Troncone R. "Formula Selection for Management of Children with Cow's Milk Allergy Influences the Rate of Acquisition of Tolerance: A Prospective Multicenter Study." The Journal of Pediatrics 163.3 (2013)

207 Canani R.B., Di Costanzo M., Bedogni G., Amoroso A., Cosenza L., Di Scala C., Granata V., and Nocerino R. "Extensively Hydrolyzed Casein Formula Containing Lactobacillus Rhamnosus GG Reduces the Occurrence of Other Allergic Manifestations in Children with Cow's Milk Allergy: 3-year Randomized Controlled Trial." Journal of Allergy and Clinical Immunology 139.6 (2017)

208 Nocerino, Rita et al.: "The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study." The Journal of pediatrics vol. 232 (2021): 183-191.e3. doi:10.1016/j.jpeds.2021.01.059

209 Koebnick, C., Wagner, I., Leitzmann, P., Stern, U., and Zunft, H. (2003). Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 17, 655-659.

210 Tilley, L., Keppens, K., Kushiro, A., Takada, T., Sakai, T., Vaneechoutte, M., and Degeest, B. (2014). A probiotic fermented milk drink containing Lactobacillus casei strain Shirota improves stool consistency of subjects with hard stools. International Journal Of Probiotics And Prebiotics 9, 23-30.

211 Dong, H., Rowland, I., Thomas, L., and Yaqoob, P. (2013). Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers. European Journal Of Nutrition 52, 1853-1863.

212 Gleeson, M., Bishop, N., Oliveira, M., and Tauler, P. (2011). Daily probiotic's (Lactobacillus casei Shirota) reduction of infection incidence in athletes. International Journal Of Sport Nutrition And Exercise Metabolism 21, 55-64.

213 Ivory, K., Chambers, S., Pin, C., Prieto, E., Arqués, J., and Nicoletti, C. (2008). Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clinical & Experimental Allergy 38, 1282-1289.

214 Nagao, F., Nakayama, M., Muto, T., and Okumura, K. (2000). Effects of a Fermented Milk Drink Containing Lactobacillus casei Strain Shirota on the Immune System in Healthy Human Subjects. Bioscience, Biotechnology And Biochemistry 64, 2706-2708.

215 Rao A.V., Bested A.C, Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., and Logan A.C. "A Randomized, Double-blind, Placebo-controlled Pilot Study of a Probiotic in Emotional Symptoms of Chronic Fatigue Syndrome." Gut Pathogens 1.1 (2009): 6.

216 Kato-Kataoka A., Nishida K., Takada M., Suda K., Kawai M., Shimizu K., Kushiro A., Hoshi R., Watanabe O., Igarashi T., Miyazaki K., Kuwano Y., and Rokutan K. "Fermented Milk Containing Lactobacillus Casei Strain Shirota Prevents the Onset of Physical Symptoms in Medical Students under Academic Examination Stress." Beneficial Microbes 7.2 (2016): 153-56.

Ce Guide Clinique est disponible en ligne à **www.ProbioticChart.ca**

Pour des questions concernant le contenu, contactez l'auteure Dragana Skokovic-Sunjic **DSunjic@bhsoftinc.com**

Pour commander plus de exemplaires de ce Guide, contactez **info@bhsoftinc.com**

AEProbio
Alliance for Education on Probiotics

Ce Guide Clinique est possible par une bourse éducative illimitée de l'Alliance for Education on Probiotics.

L'inclusion des produits dans ce Guide est basée sur les preuves scientifiques de ceux-ci et n'est pas influencée par ou limitée aux membres de l'Alliance for Education on Probiotics (AEProbio)

Members de l'alliance Canada

Bio-K+ PLUS MD
BioGaia Groundbreaking probiotics Driven by science
Nestlé Nutrition
Nutramigen A+
P&G

Members de l'alliance Etats-Unis

P&G
Bio-K+ PLUS MD
ExeGi PHARMA
DSM BRIGHT SCIENCE. BRIGHTER LIVING.

AEProbio

Alliance for Education on Probiotics

AEProbio (the Alliance for Education on Probiotics) se consacre à établir les probiotiques comme une thérapie qui convient à la protection, la restauration et l'amélioration de la santé humaine. Chaque année, nous fournissons un examen impartial et un résumé des preuves scientifiques disponibles sur l'efficacité des produits spécifiques probiotiques.

www.AEProbio.com

Visitez le site web du Guide des probiotiques

Téléchargez l'appli:

Available on the App Store

ANDROID APP ON Google Play

Votre ressource de confiance pour la sélection des probiotiques.